← Trials/Trial dossier/NCT01562678

CompletedPhase 4Results posted

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

Enrollment

28

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

BMI 18-25

Primary endpoint

Change Between Highly Desirable

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01562678
Org study ID2011P000280

Timeline

Milestones

Study first posted2012-03-26estimated
Last update posted2017-05-31actual
Results first posted2017-05-31actual
Study start2012-03 (month precision)
Primary completion2014-05actual (month precision)
Study completion2014-05actual (month precision)

Assets

Investigational agents

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Subjects will be men and women between the ages of 18 and 65. The following table list inclusion criteria for each group (lean diabetic and obese diabetic). Subjects must meet either HbA1c or fasting plasma glucose (FPG) criteria.

Lean diabetic:

BMI: 18-25 kg/m2 HbA1c: < 8.9% Fasting plasma glucose: <250 mg/dL Other inclusion criteria: On dietary modification and/or metformin

Obese diabetic:

BMI: >27 kg/m2 HbA1c: < 8.9% Fasting plasma glucose: <250 mg/dL Other inclusion criteria: On dietary modification and/or metformin

Additionally, women participants must use double barrier methods to prevent pregnancy (diaphragm with intravaginal spermicide, cervical cap, male or female condom with spermicide). If a woman suspects that she has become pregnant at any time or does not use one of the contraceptive methods recommended by the investigator, she must notify the study staff. If a woman becomes pregnant, she will be withdrawn from the study. The study staff will follow the progress of her pregnancy and the birth of her child.

Exclusion criteria

1. Uncontrolled diabetes (HbA1c>8.9%, or FPG>250 mg/dL)

2. Women who are breastfeeding, pregnant, or wanting to become pregnant.

3. Women using IUD

4. Any change in the dosage of hormonal contraceptive medications (birth control pills, implanon). Subjects should remain on same medication/ same dose during the time of the entire study.

5. Moderate (creatinine clearance of 30-59 ml/min) and severe renal impairment (creatinine clearance below 30 ml/min) and end-stage renal disease

6. Moderate, or severe hepatic impairment

7. Hypersensitivity to the active substance or any of the excipients in liraglutide

8. History of diabetic ketoacidosis

9. Congestive heart failure

10. Inflammatory conditions like inflammatory bowel disease, Rheumatoid arthritis etc

11. Gastroparesis

12. Pancreatitis

13. Gallstones- as they may cause increased risk of pancreatitis

14. Alcohol consumption- the maximum quantity for men is 140g-210g per week. For women, the range is 84g-140g per week or drinking as consuming no more than two drinks a day for men and one for women. Alcohol can cause increased risk of pancreatitis and hypoglycemia.

15. Untreated thyroid disease like hypothyroidism or hyperthyroidism

16. Subjects taking the following medications: warfarin, steroids (inhaled or systemic due to reduced hypoglycemic effect), and subjects on other hormones (LHRH analogs etc).

17. Subjects on any oral anti-diabetic agent except metformin

18. Personal or family history of MEN II or medullary thyroid cancer

19. Subjects with any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers, neuron or biostimulators, electronic infusion pumps, etc.)

20. Subjects with any type of metallic implant that could potentially be displaced or damaged during MRI, such as aneurysm clips, metallic skull plates, surgical implants etc. or metal containing tattoos

21. Anxiety and/or claustrophobia

22. Uncontrolled cardiac impairment, circulatory impairment, or inability to perspire (poor thermoregulatory function)

23. Significant sensory or motor impairment

24. Epilepsy, particularly photo-sensitive epilepsy, which may place the individual at a higher risk for adverse events during fMRI scanning with visual stimulation

25. Subjects with neurological problems which may interfere with or complicate testing (e.g. presence of titubation)

26. Body weight above the limitation of the MRI scanning table (330lbs/150 Kg) or body dimensions that could difficult the performance of the scan.

27. Subjects who cannot adhere to the experimental protocol for any reason

28. Anemia with Hgb less than 10

29. Uncontrolled infectious diseases (e.g. HIV, hepatitis, chronic infections etc)

30. Any uncontrolled endocrine condition, e.g Cushing's, Acromegaly, etc

31. Any cancers or lymphoma

32. Eating disorders like anorexia, bulimia

33. Severe hypertriglyceridemia (triglycerides >500 mg/dl)

34. Weight loss surgery or gastrectomy

35. Any changes in medications that affect brain function, e.g. anti-depressants, anti-psychotics, anti-anxiety, anti-seizure medications, antihypertensives etc (subjects should remain on same medication/ same dose during the time of the entire study).

36. Irregular periods, defined as cycle length less than 22 days or more than 40 days.

37. Any change in smoking status.

38. Vegetarians- as food images presented will include numerous non-vegetarian items and thus will not be appealing as high calorie food items.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
1
Other (unclassified)
1

Other clinical outcomes

1 endpoint
Primary/registry result

Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization

Time frame:18 days of Liraglutide or placebo treatment

change from baseline, descriptive

Posted result

GroupValue (mean), z-scores of activation in cortex95% CI
Liraglutide-0.42
Placebo0.53

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization

Time frame:18 days of Liraglutide or placebo treatment

change from baseline, descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.